ARS Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by ARS Pharmaceuticals, Inc. on June 20, 2024. The record date for the meeting was April 24, 2024, with 96,894,394 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors - Three Class I directors were elected to serve until the 2027 Annual Meeting.
- Rajeev Dadoo, Ph.D.: 68,926,825 votes For; 3,495,706 votes Withheld; 7,640,268 Broker Non-Votes.
- Michael Kelly: 67,689,553 votes For; 4,529,561 votes Withheld; 7,843,685 Broker Non-Votes.
- Pratik Shah, Ph.D.: 66,262,274 votes For; 5,956,840 votes Withheld; 7,843,685 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 79,993,516
- Votes Against: 32,172
- Abstentions: 37,111
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the three elected directors (Dadoo, Kelly, Shah) have accepted their roles and will serve until 2027.
- Verification of the significant number of broker non-votes (approx. 7.6M to 7.8M per director) relative to the total shares outstanding.
- Confirmation that Ernst & Young LLP has formally accepted the engagement for the 2024 fiscal year.